Skip to main content
Contact Us
Subscribe
E-Edition
88°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Century Therapeutics Inc
(NQ:
IPSC
)
1.790
+0.040 (+2.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Century Therapeutics Inc
< Previous
1
2
3
Next >
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
August 15, 2024
Via
Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
August 08, 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
5 Analysts Assess Century Therapeutics: What You Need To Know
June 04, 2024
Via
Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
April 11, 2024
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D...
Via
Benzinga
Century Therapeutics: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Recap: Century Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
Century Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Analyst Ratings for Century Therapeutics
April 13, 2023
Via
Benzinga
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 14, 2024
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
February 22, 2024
While not on everyone’s radar, these enticing entities just might deliver the goods.
Via
InvestorPlace
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
January 22, 2024
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these...
Via
Benzinga
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
December 19, 2023
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &...
Via
Benzinga
Topics
ETFs
Century Therapeutics's Return On Capital Employed Overview
March 20, 2023
Via
Benzinga
Where Century Therapeutics Stands With Analysts
March 16, 2023
Via
Benzinga
8 Analysts Have This to Say About Century Therapeutics
January 06, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
December 27, 2022
Via
Benzinga
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
December 05, 2023
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler.
Via
InvestorPlace
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach
November 27, 2023
Why Are Gamma-Delta T Cells Important In Fighting Cancer?
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
August 28, 2023
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares...
Via
Benzinga
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results
August 10, 2023
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 19, 2023
On Thursday, 29 stocks made new 52-week lows.
Via
Benzinga
5 Health Care Stocks That Are Diving - And May Rally
January 19, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
January 12, 2023
On Thursday, 13 stocks hit new 52-week lows.
Via
Benzinga
Top 5 Health Care Stocks That May Surge
January 10, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
January 06, 2023
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.
Via
InvestorPlace
Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive
January 06, 2023
Via
Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
December 20, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.